Position Overview

We are seeking an experienced and visionary Hematologist/Oncologist to serve as the Director of the Center for Blood Disorders and Cellular Therapy at the Providence Swedish Cancer Institute (PSCI). The successful candidate will lead our efforts in treating hematologic malignancies and non-malignant blood disorders, while advancing our cellular therapy program. This role offers the opportunity to collaborate with the Center for Immuno-Oncology and the Paul G. Allen Research Center, fostering interdisciplinary research and clinical innovation.

Key Responsibilities

• Clinical Leadership
  • Oversee and coordinate clinical care for patients with blood disorders and hematologic malignancies
  • Develop and implement treatment protocols and clinical pathways
  • Ensure adherence to quality and safety standards in patient care
  • Collaborate with the Center for Immuno-Oncology on overlapping treatment modalities
• Program Development
  • Lead the expansion of our cellular therapy program, including CAR T-cell therapy and stem cell transplantation
  • Collaborate with research teams to bring innovative therapies from bench to bedside
  • Identify opportunities for program growth and new service lines
  • Foster partnerships with other centers within the Swedish Health System and Providence Health System
• Research and Innovation
  • Direct and participate in clinical trials related to hematology and cellular therapies
  • Foster collaborations with other research institutions and industry partners
  • Publish and present research findings at national and international conferences
  • Work closely with the Paul G. Allen Research Center to integrate personalized medicine approaches into hematology/oncology care
• Administrative Duties
  • Manage the center’s budget and resources
  • Recruit, mentor, and develop clinical and research staff
  • Ensure compliance with regulatory requirements and accreditation standards
  • Participate in strategic planning for PSCI and the broader Swedish Health System
• Education and Outreach
  • Contribute to the education of fellows, residents, and medical students
  • Represent PSCI at professional meetings and community events
  • Engage in patient education initiatives and support groups
  • Promote awareness of PSCI’s programs within the Seattle community and beyond

Qualifications

• MD or DO with board certification in Hematology and Medical Oncology
• Minimum of 10 years of post-fellowship experience in hematology/oncology
• Proven track record in clinical research, particularly in cellular therapies
• Strong leadership and administrative experience in an academic or large community cancer center
• Excellence in clinical care, research, and teaching
• Demonstrated ability to build and lead multidisciplinary teams

Preferred Qualifications

• Experience with CAR T-cell therapy and stem cell transplantation programs
• History of successful grant funding and publications in peer-reviewed journals
• Familiarity with quality improvement methodologies and value-based care models
• Experience in developing partnerships across healthcare systems

Benefits

• Competitive salary commensurate with experience
• Comprehensive benefits package including health, dental, and vision insurance
• Retirement savings plan with employer match
• Paid time off and sabbatical opportunities
• Relocation assistance
• Professional development funds and opportunities
• Malpractice insurance coverage

About Providence Swedish Cancer Institute

The Providence Swedish Cancer Institute (PSCI) is a leading cancer care and research center in the Pacific Northwest. Established in 1932, PSCI has been at the forefront of cancer treatment and research for over 90 years. Our institute is committed to providing comprehensive, patient-centered care and advancing innovative treatments in oncology and hematology. PSCI treats more cancer cases than any other provider in the Pacific Northwest and is recognized for its personalized, multidisciplinary approach to patient care.

The Center for Blood Disorders & Cellular Therapy

The Center for Blood Disorders & Cellular Therapy at PSCI is a state-of-the-art facility dedicated to the treatment of hematologic malignancies and non-malignant blood disorders. Our center is at the cutting edge of cellular therapies, including CAR T-cell therapy and stem cell transplantation. We offer a comprehensive range of services, from diagnosis and treatment to long-term follow-up care, supported by a multidisciplinary team of experts.

Swedish Health System

Swedish Health System is the largest nonprofit healthcare provider in the Greater Seattle area. Founded in 1910, Swedish has grown into a comprehensive healthcare system with five hospital campuses, ambulatory care centers, and a network of more than 100 primary care and specialty clinics throughout the Greater Seattle area. Swedish is known for its commitment to innovation, quality care, and community service.

Serving our communities through exceptional, personalized care for more than 100 years
Since our beginnings in 1910, Swedish has been the region’s standard-bearer for the highest-quality health care at the best value.

Swedish is the largest nonprofit health care provider in the greater Seattle area with five hospital campuses: First Hill, Cherry Hill, Ballard, Edmonds and Issaquah. We also have ambulatory care centers in Redmond and Mill Creek, and a network of more than 100 primary care and specialty clinics throughout the greater Puget Sound area.

Swedish’s innovative care has made it a regional referral center for leading-edge procedures such as robotic-assisted surgery and personalized treatment in cardiovascular care, cancer care, neuroscience, orthopedics, high-risk obstetrics, pediatric specialties, organ transplantation and clinical research.

Swedish is affiliated with Providence St. Joseph Health, a Catholic, not-for-profit organization founded by the Sisters of Providence in 1856. With more than 122,000 employees, Providence operates 51 hospitals and 475 physician clinics across seven states. Based in Renton, Washington, Providence also provides strategic and management services to integrated health-care systems in Alaska, California, Montana, New Mexico, Oregon, Texas and Washington.

Providence Health System

Swedish Health System is part of Providence, a not-for-profit network of hospitals, care centers, health plans, physicians, clinics, home health care, and affiliated services. As the third-largest health system in the United States, Providence is committed to improving the health of communities across Alaska, California, Montana, New Mexico, Oregon, Texas, and Washington.

At Providence, we use our voice to advocate for vulnerable populations and needed reforms in health care. We are also pursuing innovative ways to transform health care by keeping people healthy, and making our services more convenient, accessible and affordable for all. In an increasingly uncertain world, we are committed to high-quality, compassionate health care for everyone – regardless of coverage or ability to pay. We help people and communities benefit from the best health care model for the future – today.

Together, our 122,000 caregivers (all employees) serve in 51 hospitals, 1,000 clinics and a comprehensive range of health and social services across Alaska, California, Montana, New Mexico, Oregon, Texas and Washington.

Providence Facts & Figures

Providence Health System: Key Facts and Figures

The Providence affiliate family includes:

• Covenant Health in West Texas and New Mexico
• Facey Medical Group in Los Angeles, CA.
• Kadlec in Southeast Washington
• Pacific Medical Centers in Seattle, WA.
• Swedish Health Services in Seattle, WA.

As a comprehensive health care organization, we are serving more people, advancing best practices and continuing our more than 100-year tradition of serving the poor and vulnerable. Delivering services across seven states, Providence is committed to touching millions of more lives and enhancing the health of the American West to transform care for the next generation and beyond.

Swedish Center for Research & Innovation

Swedish Cancer Research

Clinical cancer research is a vital component of the Swedish Cancer Institute. The Swedish Cancer Institute’s research division works closely with other medical and research organizations, as well as pharmaceutical and biotech companies. We offer clinical trials through a variety of organizations and Swedish’s own physician-initiated research.

Leading the Way
Swedish Cancer Institute physician investigators and research partners are at the leading edge of the clinical trials stage of the research process. Swedish is one of the leading clinical trial sites in the western United States and is actively involved in hundreds of ongoing clinical trials involving most types of cancer. Swedish is often the only site in the Pacific Northwest—and sometimes the first in the world—to participate in many clinical trials.

Our cancer research is focused on:

• Finding new treatments and/or more effective combinations of treatments
• Identifying new methods of detecting cancer in its earliest stages
• Discovering new ways to improve the quality of life of cancer patients
• Testing new approaches to preventing cancer

Reid Investigative Therapeutics Unit

The ITU is a dedicated research unit where Providence Swedish delivers Phase 1 and First In Human therapeutics. Staffed with a dedicated team of clinicians, nurses and research staff, we are involved in the discovery and delivery of novel agents.

Our clinical research nurses work closely with each patient and their physician to provide a predictable and comfortable clinical trial experience. In addition, each clinical trial participant in has the satisfaction of knowing that they are contributing to improve the health and well-being of other patients just like themselves. Integrated internal systems ensure the smooth transition of the patient’s care and the flow of information between all of the patient’s care providers during the treatment and follow-up phases.

Research Studies

The Swedish Center for Research and Innovation supports and administers research studies throughout Swedish’s five campus locations. Founded in 1996, it serves established research programs in cancer, heart, headache, HIV/AIDS, organ transplant, perinatal, pediatrics, neurology, pain, rheumatology and many other specialties.

At any given time, there are more than 600 research studies being conducted by Swedish-affiliated clinicians and other investigators, making Swedish an active participant in the research community.

Paul G. Allen Research Center at PSCI

The Paul G. Allen Research Center, named after the late Microsoft co-founder and philanthropist, is a hub for groundbreaking cancer research at SCI. This center focuses on developing personalized medicine approaches, leveraging advanced genomics, proteomics, and bioinformatics to tailor treatments to individual patients. The center plays a crucial role in translating laboratory discoveries into clinical applications, working closely with other departments at PSCI.

The center’s multi-omics approach to research will be driven by a broad and detailed collection of clinical and genomic data, as well as comprehensive information about how individual patients respond to treatment. One data point can tell us very little; however, when combined with data from tens of thousands of patients over time, patterns will emerge that can potentially unlock the secrets of how cancer forms and grows—and reveal new, more effective ways to treat it.

Through the center, our physician researchers will launch a multi-pronged approach to cancer care centered around three pillars:

1. Understanding
   • The Initiative for Molecular and Genomic Evaluation of Cancer will expand our collection and analysis of genetic, molecular and clinical data so we can better understand how cancer evolves, evades treatment and the mechanisms that drive its development and growth.
2. Treatment
   • The Center for Immuno-oncology will develop therapies that harness a patient’s own immune system to treat cancer.
3. Prevention
   • The Initiative for Cancer Prevention and Early Detection will work to improve new methods for cancer detection and ultimately work toward cancer prevention.

Initiative for Molecular and Genomic Evaluation of Cancer (IMGEC)

The Initiative for Molecular and Genomic Evaluation of Cancer will expand our collection and analysis of genetic, molecular and clinical data so we can better understand how cancers evolve to resist treatment and the mechanisms that drive its development and growth.

Who: Hank, Kaplan, M.D., Senior Medical & Research Director; Lead, IMGEC Paul G. Allen Research Center at Providence Swedish Cancer Institute

For years we’ve treated a patient’s cancer based on how we thought it would behave over time, based on decades of data and experience treating other patients with the same type of cancer. Now, however, significant advances in DNA and RNA testing make it possible to track an individual tumor’s biologic evolution during treatment and offer therapy aimed specifically at that tumor. Through the Initiative for Molecular and Genomic Evaluation of Cancer, today’s patients will benefit directly from this timely evaluation of their disease, while future patients could have access to a new generation of treatments born from the insights we’re gaining today. We’ll build upon the industry-leading breast cancer database which contains unusually detailed clinical information on thousands of breast cancer patients treated at SCI over the past 30 years. IMGEC will expand our collection and analysis of genetic, molecular, and clinical data to several forms of cancer, allowing us to better understand the mechanisms that drive tumor development and growth.

Initiative for Cancer Prevention and Early Detection (IPED)

The Initiative for Cancer Prevention and Early Detection seeks to improve existing and develop new methods for detecting cancers early – and ultimately preventing cancer altogether––on a broader scale.

Who: Charles Drescher, M.D., Medical Director, Gynecologic Cancer Research; Lead, IPED Paul G. Allen Research Center at Providence Swedish Cancer Institute

Ultimately, preventing cancer altogether is our goal. Early detection techniques have dramatically improved survival for many cancers and offer patients hope for more successful and less toxic treatment. Finding cancers at their earliest stage provides scientists the opportunity to learn how cancers develop, and in the case of cervical cancer led to the discovery of vaccines to prevent and eradicate the disease. The Initiative for Cancer Prevention and Early Detection will enhance the cancer patient experience by improving existing and developing new early detection and prevention strategies and deploying these strategies to as many patients as possible.

Center for Immuno-oncology (CIO)

The Center for Immuno-Oncology at PSCI is dedicated to harnessing the power of the immune system to fight cancer. The CIO focuses on developing and implementing cutting-edge immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies, and cancer vaccines. This center collaborates closely with the Center for Blood Disorders & Cellular Therapy, particularly in areas such as CAR T-cell therapy.

The Center for Immuno-oncology leverages the data collected through IMGEC to develop leading-edge therapies that use the power of a patient’s own immune system to treat their cancer and spare them the potential side effects associated with chemotherapy.

Who: Kelly Paulson, M.D., Ph.D., Medical Oncologist and Researcher; Interim Lead, CIO Paul G. Allen Research Center at Providence Swedish Cancer Institute

Cancer’s most insidious trait is its ability to evade the body’s immune response by suppressing it. Yet in recent years, immunotherapy, a form of treatment that overrides that ability and empowers the immune system to fight back, has shown promise in treating many cancers. Building upon our already formidable experience with existing immunotherapies, our team of pioneering researchers at the Center for Immuno-oncology will take the next major steps forward in equipping patients’ own defenses to fight their cancer while sparing them the toxic side effects of chemotherapy. The data collected and analyzed at IMGEC will serve as the foundation for leading-edge treatment at CIO.

Seattle, WA Area

Seattle is a vibrant, diverse city known for its natural beauty, thriving tech industry, and rich cultural scene. Nestled between Puget Sound and the Cascade Mountains, Seattle offers a unique blend of urban living and outdoor recreation. The city is home to world-class institutions, a booming economy, and a highly educated workforce. With its mild climate, excellent schools, and high quality of life, Seattle is an ideal location for professionals and their families.

Seattle is a world-class city with many wonderful attractions.

The Seattle Center,  location of the 1962 World’s Fair, has become a premier destination for arts, entertainment and leisure activities.  The 74-acre campus is home to The Experience Music Project, The Chihuly Garden and Glass Museum, and The Space Needle.

Downtown Seattle hosts the Seattle Art Museum, The Seattle Symphony, and Pike Place Market. Historic Pioneer Square is the destination for the Seattle Underground Tour, and is adjacent to CenturyLink Stadium and Safeco Field. More adventuresome travelers might want to take in some of these points of interest.

For a more detailed guide of things to do, places to eat, and personal accommodations, go to VisitSeattle.org

How to Apply

This search is being led by Academic Med on behalf of Providence Swedish Cancer Institute. Academic Med’s managing principals, Jim Hagood and Gentry Zacheis, will be overseeing this recruitment.

Qualified candidates should submit the following materials:

• Current CV
• Letter of interest detailing qualifications and vision for the role
• Three professional references

Please submit applications, nominations, and inquiries to: Jim Hagood Managing Principal, Academic Med Email: jim@academic-med.com

Equal Employment Opportunity

Providence Swedish Cancer Institute, as part of the Swedish Health System and Providence Health System, is an Equal Opportunity Employer. We are committed to fostering, cultivating, and preserving a culture of diversity, equity, and inclusion.

We do not discriminate on the basis of race, color, religion, creed, national origin, ancestry, sex, gender, gender identity, gender expression, sexual orientation, age, physical or mental disability, veteran status, military obligations, marital status, genetic information, or any other legally protected category.

This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

We strongly encourage applications from candidates who can contribute to the diversity and excellence of our organization.